Kiera Liblik is a journalist who specializes in medical and pharmaceutical news. She writes for Access Family Pharmacy and 2 Minute Medicine®, providing informative articles on various health topics, including cardiovascular disease, diabetes, respiratory infections, and more. Her work aims to educate readers and keep them updated on the latest developments in the field of medicine.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Kiera's coverage predominantly revolves around scientific research and healthcare, focusing on medical breakthroughs and treatment efficacy. Her work heavily emphasizes citations of data to support the reported findings.
Given Kiera Liblik’s focus on citing data, she is likely to be interested in pitches supported by robust and credible research studies or clinical trials within the medical field. She may find value in experts who can provide detailed insights into new developments, particularly those backed by empirical evidence.
As Kiera does not have a specific geographic focus, sources from any location with access to relevant scientific or medical data could potentially capture her attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Kiera Liblik
1. In this randomized controlled trial, patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation who received dupilumab had a lower annualized rate of moderate or severe exacerbations than those who received a placebo.
By: Jayden Berdugo, Kiera Liblik
1. In this randomized controlled trial studying critically ill adults, pantoprazole use was associated with a lower risk of clinically important upper gastrointestinal bleeding compared to placebo use.
By: Jayden Berdugo, Kiera Liblik
1. In a randomized controlled trial of patients who suffered an acute ischemic stroke, the reteplase group reported a greater number of patients experiencing an excellent functional score compared to the alteplase group.
By: Nhat Hung Benjamin, Kiera Liblik
1. In this randomized controlled trial, benralizumab, an anti-interleukin-5 receptor (anti-IL-5R) monoclonal antibody, demonstrated histologic depletion of eosinophils among patients with eosinophilic esophagitis (EoE) compared to placebo.
By: Kiera Liblik, Jayden Berdugo
Originally published by 2 Minute Medicine view original article ). Reused on AccessMedicine with permission.
By: Jayden Berdugo, Kiera Liblik
1. In this randomized controlled trial, a prophylactic weekly dose of efanesoctocog alfa (ALTUVIIIO) resulted in sustained factor VIII activity in children with severe hemophilia A.
By: Nhat Hung (Benjamin) Lam
1. In this randomized controlled trial, among patients with ischemic stroke without access to thrombectomy, tenecteplase given between 4.5 and 24 hours after onset demonstrated improved disability-free survival. 2. Tenecteplase was associated with an elevated risk of symptomatic intracranial hemorrhage (ICH) compared to standard medical therapy. Evidence Rating Level: 1 (Excellent) Study Rundown: Timely treatment
By: Kiera Liblik
1. In this randomized controlled trial, in patients undergoing cardiopulmonary bypass, continuous intravenous (IV) administration of amino acids was found to be associated with lower rates of acute kidney injury (AKI).
By: Kiera Liblik
1. In this randomized controlled trial, among traumatic brain injury (TBI) patients with anemia, a liberal red-cell transfusion strategy resulted in no significant difference in neurological outcomes at six months compared with a restrictive transfusion strategy. 2. A liberal transfusion strategy was associated with improvement in several measures of functional independence and quality of life
By: Kiera Liblik
1. In this randomized cluster trial, twice-yearly azithromycin distribution reduced all-cause childhood mortality among children aged one to 59 months in rural communities in Niger.
(833) 317-6278 